Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06078709
Other study ID # GMROR2241
Secondary ID NCI-2023-07432GM
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 20, 2023
Est. completion date November 30, 2026

Study information

Verified date February 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial tests how well preoperative (prior to surgery) radiation therapy with fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX) works for the treatment of stage I-III esophageal or gastroesophageal junction adenocarcinoma. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Fluorouracil stops cells from making deoxyribonucleic acid (DNA) and it may kill tumor cells. Leucovorin is not a chemotherapy medication but is given in conjunction with chemotherapy. Leucovorin is used with the chemotherapy medication fluorouracil to enhance the effects of the fluorouracil, in other words, to make the drug work better. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Giving preoperative hypofractionated radiation with fluorouracil and oxaliplatin may kill more tumor cells in patients with stage I-III esophageal or gastroesophageal junction adenocarcinoma.


Description:

PRIMARY OBJECTIVE: I. To demonstrate non-inferiority of pathologic complete response (pCR) with hypofractionated radiotherapy and concurrent FOLFOX compared to historical controls. SECONDARY OBJECTIVES: I. Report acute grade ≥ 3 gastrointestinal (GI) toxicity, per Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. II. Assess post-operative toxicity for patients undergoing esophagectomy, as determined by the Clavien-Dindo Classification. III. Analyze patient-reported quality of life, per Functional Assessment of Cancer Therapy- Esophageal (FACT-E). IV. Determine the financial toxicity of hypofractionated radiotherapy, using Comprehensive Score for Financial Toxicity (COST-FACIT). V. Report overall survival and progression-free survival. VI. Report long-term toxicity secondary to trimodality therapy. VII. Report event-free survival. VIII. Assess outcomes for patients treated with hypofractionated radiotherapy and FOLFOX but who did not proceed to esophagectomy. IX. Compare toxicity of chemoradiation between patients receiving proton based versus (vs.) photon-based radiotherapy. CORRELATIVE OBJECTIVES: I. Explore the predictive and prognostic role for circulating tumor DNA in esophageal cancer. II. Study the utility of whole exome and germline sequencing to predict chemoradiation treatment response. III. Explore the predictive power of whole exome sequencing regarding chemoradiotherapy toxicity. IV. Implement whole exome and germline sequencing to personalize immunotherapy in esophageal cancer. V. Study the predictive and prognostic role of tumor-derived extracellular vesicles in esophageal cancer. OUTLINE: Patients receive oxaliplatin intravenously (IV) over 2-6 hours on day 1, leucovorin calcium IV over 10-120 minutes on day 1, and and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment repeats every 2 weeks for a total of 3 cycles in the absence of disease progression or unacceptable toxicity. Starting at cycle 2, patients undergo radiation therapy daily on Monday through Friday for a total of 15 treatments. Patients undergo esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS) during screening and undergo computed tomography (CT)/position emission tomography (PET) scan and CT scan as well as blood sample collection throughout the study. After completion of study treatment, patients are followed up at 6,12 and 24 months and then up to 5 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 99
Est. completion date November 30, 2026
Est. primary completion date May 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Histological confirmation of esophageal or gastroesophageal junction adenocarcinoma, American Joint Committee on Cancer (AJCC) 8th edition stage T1-4N0-3M0 - Candidate for trimodality therapy: neoadjuvant chemotherapy, chemoradiation, and esophagectomy - Surgical consultation has confirmed that patient is an appropriate candidate for esophagectomy - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 - Negative pregnancy test done = 7 days prior to chemotherapy, for women of childbearing potential only - Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance - Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) - Willing to provide blood samples for correlative research purposes Exclusion Criteria: - Clinical or biopsy-proven distant metastatic disease (AJCC 8th edition stage TanyNanyM1) - Cervical or upper esophageal tumor - Prior chemotherapy or radiotherapy for esophageal cancer or history of radiotherapy to the thorax - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with proper assessment of adverse events - Receiving any investigational agent which would be considered as a treatment for the primary neoplasm or other active malignancy = 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes - Any of the following: - Pregnant women - Nursing women - Men or women of childbearing potential who are unwilling to employ adequate contraception

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Clinical Stage I Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Esophageal Neoplasms

Intervention

Procedure:
Biospecimen Collection
Undergo blood sample collection
Computed Tomography
Undergo CT and PET/CT scan
Endoscopic Ultrasound
Undergo EUS
Esophagogastroduodenoscopy
Undergo EGD
Drug:
Fluorouracil
Given IV
Radiation:
Hypofractionated Radiation Therapy
Undergo hypofractionated radiation therapy
Drug:
Leucovorin Calcium
Given IV
Oxaliplatin
Given IV
Procedure:
Positron Emission Tomography
Undergo PET and PET/CT scan
Other:
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathologic complete response A single-group design will be used to test whether the proportion is potentially non-inferior, with a non-inferiority proportion (P0) of 0.13 (H0: P = 0.13 versus H1: P > 0.13). Up to 5 years after completion of chemoradiation
Secondary Incidence of acute = gastrointestinal (GI) adverse events (AEs) Report acute grade = 3 GI AEs per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. Will be summarized descriptively. Up to 6 weeks after completion of chemoradiation
Secondary Incidence of post operative AEs Determined by the Clavien-Dindo Classification. Will be summarized descriptively. From surgery up to 6 months after completion of chemoradiation
Secondary Patient-reported quality of life (QOL) Per Functional Assessment of Cancer Therapy- Esophageal. Will be assessed over time. Wilcoxon signed-rank tests will be used to calculate p-values. Descriptive statistics and graphical methods will also be used to summarize the data. Up to 24 months after completion of chemoradiation
Secondary Financial toxicity Financial toxicity will be measured using the COmprehensive Score for financial Toxicity (COST), a patient-reported outcome measure that describes the financial distress experienced by cancer patients. The survey consists of 12 questions, each answered with a 0-4 scale where 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, and 4=Very much. Results will be reported descriptively and include separate consideration of individual item scores. Up to 24 months after completion of chemoradiation
Secondary Overall survival (OS) Will be assessed graphically using the Kaplan-Meier method. Summary statistics will be reported, including medians, 95% confidence intervals, etc. From study entry to death from any cause, up to 5 years after completion of chemoradiation
Secondary Progression-free survival (PFS) Will be assessed graphically using the Kaplan-Meier method. Summary statistics will be reported, including medians, 95% confidence intervals, etc. From study entry to the first of either disease progression or death, up to 5 years after completion chemoradiation
Secondary Long-term toxicity secondary to trimodality therapy Will be reported descriptively using CTCAE version 5.0 criteria. Up to 5 years after completion of chemoradiation
Secondary Event free survival Will be assessed graphically using the Kaplan-Meier method. Summary statistics will be reported, including medians, 95% confidence intervals, etc. From study entry to the first of either disease progression or recurrence or relapse or death, up to 5 years after completion of chemoradiation
Secondary Outcomes for patients treated with hypofractionated radiotherapy and FOLFOX but who did not proceed to esophagectomy OS and PFS will be assess using Kaplan-Meier methodology. Summary statistics will be reported, including medians, 95% confidence intervals, etc. AEs and QOL data will be reported with summary statistics and graphical methods, as appropriate. Up to 5 years after completion of chemoradiation
Secondary Toxicity of chemoradiation between patients receiving proton based versus photon-based radiotherapy Will be done descriptively, reporting frequencies and percentages between patients. Up to 5 years after completion of chemoradiation
Secondary Toxicity of chemoradiation between groups receiving proton based versus photon-based radiotherapy Will be done descriptively, reporting toxicity rates between groups using the chi-square test. Up to 5 years after completion of chemoradiation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04522336 - Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer Phase 1
Active, not recruiting NCT03641313 - Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Phase 2
Not yet recruiting NCT05296005 - Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers Phase 1
Suspended NCT03604991 - Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery Phase 2/Phase 3
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Recruiting NCT05651594 - Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03801876 - Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Phase 3
Recruiting NCT04391049 - Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Phase 1
Recruiting NCT04660760 - Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03776487 - Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer Phase 2
Recruiting NCT06203600 - Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Phase 2/Phase 3
Active, not recruiting NCT04929392 - Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer Phase 2
Recruiting NCT05677490 - mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Phase 3
Recruiting NCT03784326 - Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma Phase 2
Recruiting NCT05041153 - Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Early Phase 1
Recruiting NCT04007744 - Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05836584 - Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer Phase 2
Active, not recruiting NCT04097028 - Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma Phase 2
Recruiting NCT04704661 - Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Phase 1